Mirabegron Shows No Increased Obesity-Related Neoplasm Risk in Overactive Bladder

This study finds that mirabegron, used for overactive bladder, is not associated with a higher risk of obesity-related neoplasms compared to antimuscarinics. However, the analysis indicates an increase in all-cause mortality among mirabegron users. These findings highlight the need for further investigation into the safety profile of mirabegron beyond cancer risk.

Originally published by gnews